RECRUITING

Regulating Together in Tuberous Sclerosis Complex

Study Overview

This clinical trial focuses on testing the efficacy of different digital interventions to promote re-engagement in cancer-related long-term follow-up care for adolescent and young adult (AYA) survivors of childhood cancer.

Description

The purpose of this study is to use a program called Regulating Together (RT), a remote, non-pharmacologic intervention to treat symptoms of emotion dysregulation in children and adolescents with Tuberous Sclerosis Complex (TSC) and TSC-Associated Neuropsychiatric Disorder (TAND).

Official Title

Regulating Together in Tuberous Sclerosis Complex: A Pilot Feasibility Study in Children and Adolescents With TSC-Associated Neuropsychiatric Disorder (TAND)

Quick Facts

Study Start:2023-12-20
Study Completion:2026-12-20
Study Type:Not specified
Phase:Not Applicable
Enrollment:Not specified
Status:RECRUITING

Study ID

NCT06105736

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Ages Eligible for Study:8 Years to 17 Years
Sexes Eligible for Study:ALL
Accepts Healthy Volunteers:No
Standard Ages:CHILD
Inclusion CriteriaExclusion Criteria
  1. * Children ages 8-17 years inclusive with a documented clinical and/or genetic diagnosis of TSC and exhibiting symptoms of behavioral dysregulation (identified on the TAND Checklist having temper tantrums, aggressive outbursts, self-injury, and/or impulsivity) are eligible for inclusion.
  2. * Participants and their caregivers have access to a computer, phone, or tablet with video capability and stable internet connection. If lack of a device or internet service is the sole barrier to eligibility/participation, interested individuals will be connected to a TSC Clinic social worker to link them to existing government and charity programs specifically addressing this disparity in underserved communities and households in need (e.g., the Affordable Connectivity Program).
  3. * Participants must also be willing to participate in treatment sessions and have minimal levels of functional verbal communication (child and their caregiver must be fluent in English
  4. * Child must have a minimum IQ\>65 on the WASI-II at the screening/baseline visit).
  1. * Participants be on a stable medication regimen at least 4 weeks prior to enrollment
  2. * Do not have a plan to start a new psychosocial intervention (e.g., individual psychotherapy, family psychotherapy, group psychotherapy or social skills training) or behavior medication within 30 days prior to enrollment or at any point during the study. ----Participants with significant disruptive, aggressive, self-injurious or sexually inappropriate behaviors deemed potentially dangerous or overly disruptive to the group dynamic/session, having significant co-occurring neuropsychiatric illness warranting other treatment approaches as determined by study clinician (e.g., substance use disorders, psychotic disorders, schizophrenia), or having significant sensory impairment that would limit participation in intervention curriculum/materials (e.g., blindness or uncorrected hearing loss) also will be excluded.

Contacts and Locations

Study Contact

Jamie Capal, MD
CONTACT
(919) 966-9343
jamie.capal@cidd.unc.edu

Principal Investigator

Jamie Capal, MD
PRINCIPAL_INVESTIGATOR
University of North Carollina at Chapel Hill

Study Locations (Sites)

University of North Carolina Chapel Hill-Carolina Institute for Developmental Disabilities
Carrboro, North Carolina, 27510
United States
Cincinnati Children's Hospital Medical Center (CCHMC)
Cincinnati, Ohio, 45229
United States

Collaborators and Investigators

Sponsor: University of Rochester

  • Jamie Capal, MD, PRINCIPAL_INVESTIGATOR, University of North Carollina at Chapel Hill

Study Record Dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Registration Dates

Study Start Date2023-12-20
Study Completion Date2026-12-20

Study Record Updates

Study Start Date2023-12-20
Study Completion Date2026-12-20

Terms related to this study

Additional Relevant MeSH Terms

  • TSC
  • Behavioral Symptoms